Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃

Introduction

Arrhythmias, as a common and potentially fatal cardiovascular disease, pose a serious threat to the lives and health of people worldwide. Although several existing antiarrhythmic drugs have achieved certain clinical efficacy, their side effects and resistance issues still restrict the improvement of treatment outcomes. Natural products, due to their structural diversity and rich biological activity, have become important resources for the development of antiarrhythmic drugs. Denudatine, a natural alkaloid isolated from plants of the genera Aconitum and Delphinium spp., has recently attracted widespread attention in pharmacology and medicinal chemistry due to its regulatory effects on ventricular fiber action potentials and its inhibitory effect on arrhythmic effects of aconitine. This paper systematically reviews the chemical structure, plant origin, pharmacological activity, mechanism of action, and druggability evaluation of Glosphepherin, aiming to provide theoretical basis and research directions for the drug development and clinical application of this natural product.

Chemical structure and physicochemical properties

Denudatine, CAS number 26166-37-0, is a natural alkaloid with a complex polycyclic structure, molecular formula C20H27NO4, and molecular weight 343.5110. Its structural core is a typical dihydroisoquinoline skeleton, containing multiple chiral centers that give it high stereochemical properties. The LogP value of light celeferine is 2.8560, indicating moderate lipid solubility, which is beneficial for cell membrane penetration and distribution in the body. Its topological pole surface area (TPSA) is 43.7 Ų, indicating moderate molecular polarity that facilitates binding to biomacromolecules. It has low water solubility (0.1677 mg/mL), but its high lipid solubility and low polarity give it excellent membrane permeability. Notably, light celeferine exhibits high blood-brain barrier permeability, suggesting potential central nervous system activity or side effect risks. The hERG channel inhibition test was negative, indicating a low risk of cardiotoxicity, while the Ames mutagenic test result was 0.0, indicating no significant genotoxicity.

Plant Origins and Extraction Methods

Glosphorinus is mainly found in plants of the genera Aconitum and Delphinium, which are widely distributed in temperate and subarctic regions, especially abundant in southwestern China and the Himalayas. Aconite plants have long been used in traditional Chinese medicine due to their various alkaloids, possessing multiple pharmacological effects such as analgesic, anti-inflammatory, and cardiovascular regulation.

The extraction of lufinine is usually done by solvent extraction combined with column chromatography separation. First, after crushing dried plant rhizomes or whole plants, reflux extraction is performed using ethanol or methanol as solvents. The extract is concentrated and the pH is adjusted by acid-base methods to separate alkaline alkaloids. Subsequently, it was further purified by silica gel column chromatography or high-performance liquid chromatography (HPLC) to obtain high-purity lustrifeminine. In recent years, the application of ultrasound-assisted extraction and supercritical fluid extraction technologies has improved extraction efficiency and purity, reduced the use of harmful solvents, and aligned with green chemistry principles.

Pharmacological activity research

The pharmacological activity of light valquenine is mainly concentrated in the cardiovascular system, especially showing significant effects in antiarrhythmia. In vitro electrophysiological experiments show that glospheine can regulate the action potential of ventricular fibers, extend the duration of action potentials, stabilize the membrane potential of myocardial cells, and thus reduce the occurrence of abnormal excitation. Its regulatory effect on sodium and potassium channels helps restore the electrophysiological stability of myocardial cells.

Additionally, aconitine can inhibit aconitine-induced arrhythmias, a cardiac toxic alkaloid that often causes severe arrhythmias. Specterfqueline reduces the risk of arrhythmicity by antagonizing the effects of aconitine, demonstrating potential detoxifying and protective effects.

In animal experiments, chlorfinch has shown good antiarrhythmic effects, significantly reducing the frequency and severity of arrhythmic episodes. Safety evaluations have shown no significant cardiotoxicity or neurotoxicity within the effective dose range, supporting its potential as an antiarrhythmic drug candidate.

Mechanism of action and molecular targets

The antiarrhythmic mechanism of lightvaladine involves regulation of various ion channels, with main targets including KCNH2 (hERG), KCNQ1, SCN5A (cardiac sodium channel Nav1.5), CACNA1C (L-type calcium channel), KCNE1, RYR2 (intracardiac calcium release channel), and KCNE2 as key proteins.

1. Potassium channel regulation: Chloroquinine modulates the KCNH2 and KCNQ1 channels, affecting the myocardial cell repolarization process, prolonging the action potential duration, and preventing arrhythmias caused by premature repolarization. In particular, it has no inhibitory effect on the hERG channel, reducing the risk of drug-induced long QT syndrome.

2. Sodium channel regulation: By modulating the SCN5A-encoded Nav1.5 sodium channel, lufquenine reduces abnormal sodium inflow, stabilizes the membrane potential of myocardial cells, and decreases the occurrence of arrhythmias.

3. Regulation of calcium channels and calcium release: Regulation of CACNA1C and RYR2 helps maintain intracellular calcium homeostasis, preventing abnormal excitation of myocardial cells caused by calcium overload.

4. Role of auxiliary subunits: KCNE1 and KCNE2, as auxiliary subunits of potassium channels, participate in regulating the electrophysiological properties of these channels. Chloroquinine may further influence the electrical activity of myocardial cells by modulating these subunits.

In summary, lightfarrowine stabilizes the electrophysiological environment of myocardial cells through multi-target and multi-pathway synergistic effects, exerting antiarrhythmic effects.

Druggability evaluation and pharmacokinetics

The druggability parameters of photophevine indicate that it has good potential for drug development. The molecular weight is moderate, the LogP value is suitable for oral absorption, and the low TPSA facilitates cell membrane penetration. Although its water solubility is relatively low, drug formulation technology can improve its dissolution and bioavailability. High blood-brain barrier permeability suggests it may affect the central nervous system and requires special attention in safety evaluation.

hERG channel inhibition was negative, reducing potential cardiotoxicity risk, and the Ames test showed no mutagenicity, indicating good genetic safety. Preliminary pharmacokinetic studies show that glospheine has a moderate half-life and good distribution in the body, effectively reaching concentrations in myocardial tissue.

However, current research on the metabolic pathway, enzymatic transformation, and elimination mechanisms of Specterpheine remains limited. Further systematic pharmacokinetic and toxicological studies are needed in the future to provide comprehensive data support for clinical application.

Prospects and outlooks for clinical applications

Given the significant pharmacological activity and good safety profile of spectervochlorine in antiarrhythmia, it has broad prospects for future development as a novel antiarrhythmic drug. Its multi-target regulatory mechanism is expected to overcome the shortcomings of traditional drugs that rely on a single target that often leads to resistance and side effects, providing a safer and more effective treatment option.

Additionally, the inhibitory effect of light valmetine on aconitine-induced arrhythmicity suggests its potential for detoxification and synergistic effects in traditional Chinese medicine formulations, making it a key ingredient in improving the safety of traditional aconite drugs.

Future research should focus on:
- Systematic pharmacokinetic and toxicological evaluations to clarify in vivo behavior and safety boundaries;
- Preclinical animal models and early clinical trials to verify efficacy and safety;
- Optimization of formulation processes to improve bioavailability and stability;
- Explore its potential applications in other cardiovascular diseases, such as heart failure and ischemic heart disease.

Through multidisciplinary collaborative research, the transformation of glosphepheline from a natural product to a clinical drug is being promoted, meeting the urgent clinical demand for safe and effective antiarrhythmic drugs.

Conclusion

Luxfèrein, a natural alkaloid derived from plants of the genus Aconitum and Larva genus, demonstrates significant potential as a novel cardiovascular drug due to its unique chemical structure and significant antiarrhythmic activity. Its multi-target regulation of myocardial electrophysiology provides new ideas for the design of antiarrhythmic drugs. Combined with favorable druggability parameters and safety evaluation, Acantpheine is expected to play an important role in future drug development and clinical applications. In the future, in-depth research into its pharmacological mechanisms, pharmacokinetics, and clinical efficacy should be strengthened to promote its clinical translation and benefit the vast number of arrhythmia patients.